Basilea Pharmaceutica is uncertain when anti-fungal drug isavuconazole would hit the market after Japanese partner Astellas Pharma expanded a Phase III trial of the treatment, delaying the release of data for as long as 18 months. The Swiss biotech firm faced a major setback late last year after it failed to gain endorsement from the European Medicines Agency for antibiotic ceftobiprole.

Full Story:

Related Summaries